Tidal Investments LLC Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Tidal Investments LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 36.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 152,591 shares of the biopharmaceutical company's stock after buying an additional 41,127 shares during the quarter. Tidal Investments LLC's holdings in Gilead Sciences were worth $14,095,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. FMR LLC increased its position in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP increased its position in Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after buying an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC increased its position in Gilead Sciences by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after buying an additional 749,047 shares during the last quarter. Norges Bank purchased a new stake in Gilead Sciences in the fourth quarter worth $1,789,254,000. Finally, Northern Trust Corp increased its position in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the transaction, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. The trade was a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders sold 22,929 shares of company stock valued at $2,634,220. Insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GILD shares. Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. BMO Capital Markets lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada lifted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Trading Down 1.3%

Shares of NASDAQ GILD traded down $1.39 during midday trading on Wednesday, reaching $107.72. The company had a trading volume of 7,958,565 shares, compared to its average volume of 7,713,999. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm's fifty day moving average price is $105.44 and its 200-day moving average price is $100.07. The stock has a market cap of $134.00 billion, a PE ratio of 291.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) EPS. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.